TGA-ethanol Pretreated Bovine Pericardium for the Norwood Procedure
TGA-ethanol Pretreated Bovine Pericardium for the Norwood Procedure
批准号:
8013820
负责人:
Robert J Levy
金额:
$65.51万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-04-01 至 2013-03-31
关键词:
AccountingAdolescentAffectAllograftingAngiographyAnimal EuthanasiaAnimal ModelAortaBiocompatible MaterialsCardiac Catheterization ProceduresCardiac Surgery proceduresCattleChildChildhoodDevicesEthanolGlutaralGoalsHumanHypoplastic Left Heart SyndromeImageImplantInflammationInstructionInvestigationMechanicsMedical Care CostsMicroscopicModelingMorphologyNational Heart, Lung, and Blood InstituteOutcomePericardial body locationPhasePhysiologicalPlant RootsProceduresPropertyPulmonary artery structureResearchResistanceSamplingSheepSiteSpecimenStagingTestingThrombosisTissuesUnited StatesXenograft procedurebasebiomaterial compatibilitycalcificationcongenital heart disordercrosslinkimprovedindexingnovelpericardial sacpreclinical studyprogramsrepaired
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
The Norwood staged repair for hypoplastic left heart syndrome (HLHS) has saved the lives of thousands of children. Stage I of this procedure involves augmenting the underdeveloped aorta, and at present this is done using either cryopreserved human allograft material (pulmonary artery or aorta) or glutaraldehyde pretreated bovine pericardium. The proposed research will investigate using bovine pericardium, pretreated with a novel cross-linker, triglycidylamine (TGA), synthesized by our group. TGA, when used to crosslink heterograft biomaterials, confers stability, biocompatibility, calcification resistance and mechanical properties that are superior to glutaraldehyde, the cross-linker used to prepare clinically used heterograft biomaterials. In addition we will use TGA in combination with ethanol pretreatment, which confers additional calcification resistance. TGA-ethanol pretreated bovine pericardium is hypothesized to be a better candidate material than glutaraldehyde fixed bovine pericardium for Stage I Norwood aortic augmentation because of a number of advantages of TGA cross-linking compared to glutaraldehyde including greater material stability, mechanical properties more comparable to native tissue and calcification resistance. The goal of these investigations is to carry out preclinical studies in a sheep model under GLPs for submission to the FDA for an IDE for a TGA-ethanol pretreated bovine pericardium implant. This will be the basis of our competitive Phase 2 submission following the conclusion of the proposed initial two year NHLBI C-TRIP program. Specific Aim 1. Prepare and characterize TGA-ethanol pretreated bovine pericardium. This material will be compared with the currently manufactured glutaraldehyde pretreated bovine pericardium (control implants). Endpoints will include indices of crosslink stability, microscopic morphology and mechanical properties per unaxial testing. Specific Aim 2. Carry out animal model studies of the Norwood I aortic root augmentation procedure using TGA-ethanol pretreated bovine pericardium versus glutaraldehyde pretreated bovine pericardium (controls) in juvenile sheep with survival to 150 days. Prior to euthanasia animals will undergo a cardiac catheterization and angiography procedure in order to obtain physiologic endpoints and imaging studies of the aortic augmentation site comparing two types of xenograft implants. Specific Aim 3. Explantation at 150 days will be followed by analyses of aortic augmentation specimens for a number of endpoints including macroscopic and microscopic assessment of material integrity, calcification, thrombosis, and inflammation. Calcification analyses will be carried out on explants and samples will also be studied for changes in mechanical properties compared to unimplanted material parameters. RELEVANCE (See instructions): Congenital heart disease affects thousands of children in the United States, and accounts for billions of dollars in medical care costs. This proposal will investigate a new pediatric cardiac surgery device, a TGA-ethanol pretreated bovine pericardial xenograft, that may improve outcomes for the most severe form of congenital heart disease, the hypoplastic left heart syndrome.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Medical Device Consortium at the Children's Hospital of Philadelphia
-
批准号:10683865
-
项目类别:
-
资助金额:$15.0万
-
财政年份:2018
-
负责人:Robert J Levy
-
依托单位:
Medical Device Consortium at the Children's Hospital of Philadelphia
-
批准号:9768955
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2018
-
负责人:Robert J Levy
-
依托单位:
Medical Device Consortium at the Children's Hospital of Philadelphia
-
批准号:10466822
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2018
-
负责人:Robert J Levy
-
依托单位:
Medical Device Consortium at the Children's Hospital of Philadelphia
-
批准号:10468507
-
项目类别:
-
资助金额:$15.0万
-
财政年份:2018
-
负责人:Robert J Levy
-
依托单位:
Medical Device Consortium at the Children's Hospital of Philadelphia
-
批准号:10247486
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2018
-
负责人:Robert J Levy
-
依托单位:
High Field Gradient Targeting Magnetic Nanoparticle Loaded Cells to Stents
-
批准号:8103513
-
项目类别:
-
资助金额:$25.13万
-
财政年份:2011
-
负责人:Robert J Levy
-
依托单位:
High Field Gradient Targeting Magnetic Nanoparticle Loaded Cells to Stents
-
批准号:8270523
-
项目类别:
-
资助金额:$20.53万
-
财政年份:2011
-
负责人:Robert J Levy
-
依托单位:
TGA-ethanol Pretreated Bovine Pericardium for the Norwood Procedure
-
批准号:7867658
-
项目类别:
-
资助金额:$65.35万
-
财政年份:2010
-
负责人:Robert J Levy
-
依托单位:
Blood Outgrowth Endothelial Cell Seeding of Heart Valve Leaflets
-
批准号:7894729
-
项目类别:
-
资助金额:$47.77万
-
财政年份:2009
-
负责人:Robert J Levy
-
依托单位:
Blood Outgrowth Endothelial Cell Seeding of Heart Valve Leaflets
-
批准号:7653208
-
项目类别:
-
资助金额:$48.06万
-
财政年份:2009
-
负责人:Robert J Levy
-
依托单位:
Biocompatible Heterograft Biomaterials
-
批准号:7354819
-
项目类别:
-
资助金额:$62.24万
-
财政年份:2007
-
负责人:Robert J Levy
-
依托单位:
Genetic Mechanisms in Pediatric Heart Disease
-
批准号:7017069
-
项目类别:
-
资助金额:$386.08万
-
财政年份:2004
-
负责人:Robert J Levy
-
依托单位:
Genetic Mechanisms in Pediatric Heart Disease
-
批准号:7354828
-
项目类别:
-
资助金额:$371.45万
-
财政年份:2004
-
负责人:Robert J Levy
-
依托单位:
Biocompatible Heterograft Biomaterials
-
批准号:6772276
-
项目类别:
-
资助金额:$61.46万
-
财政年份:2004
-
负责人:Robert J Levy
-
依托单位:
Genetic Mechanisms in Pediatric Heart Disease
-
批准号:7174736
-
项目类别:
-
资助金额:$384.56万
-
财政年份:2004
-
负责人:Robert J Levy
-
依托单位:
Genetic Mechanisms in Pediatric Heart Disease
-
批准号:6854546
-
项目类别:
-
资助金额:$385.43万
-
财政年份:2004
-
负责人:Robert J Levy
-
依托单位:
Genetic Mechanisms in Pediatric Heart Disease
-
批准号:6698902
-
项目类别:
-
资助金额:$389.15万
-
财政年份:2004
-
负责人:Robert J Levy
-
依托单位:
Gene Delivery Stents
-
批准号:6696325
-
项目类别:
-
资助金额:$45.81万
-
财政年份:2003
-
负责人:Robert J Levy
-
依托单位:
Gene Delivery Stents
-
批准号:7046073
-
项目类别:
-
资助金额:$46.8万
-
财政年份:2003
-
负责人:Robert J Levy
-
依托单位:
Gene Delivery Stents
-
批准号:8208025
-
项目类别:
-
资助金额:$40.82万
-
财政年份:2003
-
负责人:Robert J Levy
-
依托单位:
海外基金